umbralisib
Sign in to saveAlso known as RP-5264, TGR-1202, RP5264, TGR1202
Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
~4 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Adverse effects
- History
- Society and culture
- Legal status
- References
- External links
Umbralisib, sold under the brand name Ukoniq, is an anti-cancer medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
Umbralisib is a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon.
Excerpted from Wikipedia’s “umbralisib” article, available under the CC BY-SA 4.0 licence.